Your browser is no longer supported. Please, upgrade your browser.
Settings
BCEL Atreca, Inc. daily Stock Chart
BCEL [NASD]
Atreca, Inc.
Index- P/E- EPS (ttm)-2.19 Insider Own6.87% Shs Outstand24.39M Perf Week1.57%
Market Cap361.95M Forward P/E- EPS next Y-2.60 Insider Trans0.00% Shs Float14.58M Perf Month0.95%
Income-59.40M PEG- EPS next Q-0.64 Inst Own86.10% Short Float5.70% Perf Quarter38.56%
Sales- P/S- EPS this Y-37.80% Inst Trans-0.06% Short Ratio6.49 Perf Half Y-7.31%
Book/sh7.33 P/B2.02 EPS next Y31.40% ROA- Target Price28.20 Perf Year-
Cash/sh8.24 P/C1.80 EPS next 5Y- ROE- 52W Range9.51 - 23.65 Perf YTD-4.07%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-37.25% Beta-
Dividend %- Quick Ratio27.40 Sales past 5Y- Gross Margin- 52W Low56.05% ATR1.69
Employees102 Current Ratio27.40 Sales Q/Q- Oper. Margin- RSI (14)52.24 Volatility7.77% 12.48%
OptionableNo Debt/Eq0.00 EPS Q/Q-57.80% Profit Margin- Rel Volume1.60 Prev Close15.84
ShortableYes LT Debt/Eq0.00 EarningsNov 12 Payout- Avg Volume128.08K Price14.84
Recom1.70 SMA20-2.50% SMA5011.98% SMA2006.62% Volume205,474 Change-6.31%
Sep-04-19Initiated ROTH Capital Buy $30
Jul-15-19Initiated Stifel Buy $28
Jul-15-19Initiated Evercore ISI Outperform
Jul-15-19Initiated Cowen Outperform
Jul-15-19Initiated Canaccord Genuity Buy $23
Dec-26-19 10:48AM  These new Bay Area stocks from 2019 are 'underwater' as year ends American City Business Journals +16.91%
Dec-19-19 04:54PM  Hedge Funds Staying Clear Of Atreca, Inc. (NASDAQ:BCEL) Insider Monkey -9.02%
Dec-03-19 08:00AM  Atreca Announces FDA Clearance of Investigational New Drug Application for ATRC-101 GlobeNewswire +32.34%
Nov-14-19 08:00AM  Atreca to Present at Two Upcoming Investor Conferences GlobeNewswire
Nov-12-19 04:05PM  Atreca Reports Third Quarter 2019 Financial Results and Recent Corporate Developments GlobeNewswire
Nov-05-19 08:00AM  Atreca to Highlight ATRC-101 Preclinical Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Sep-19-19 09:19AM  Do Institutions Own Shares In Atreca, Inc. (NASDAQ:BCEL)? Simply Wall St.
Aug-26-19 04:05PM  Atreca Announces Appointment of Dr. Lindsey Rolfe to its Board of Directors GlobeNewswire -6.49%
Aug-17-19 07:30AM  Stanford University Now Owns Stakes in Uber and Pinterest Stock Barrons.com
Aug-13-19 04:05PM  Atreca Reports Second Quarter 2019 Financial Results and Recent Corporate Developments GlobeNewswire +25.78%
Jul-15-19 02:22PM  Stifel: Atreca Offers Attractive Oncology Drug Development Play Benzinga
Jul-11-19 08:00AM  Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer and Courtney Phillips as General Counsel GlobeNewswire
Jun-20-19 11:16AM  Atreca Opens For Trade Benzinga
Jun-19-19 09:40PM  Atreca Announces Pricing of Initial Public Offering GlobeNewswire
08:20AM  Atreca IPO: What You Need To Know Benzinga
Jun-17-19 10:07AM  IPO Outlook For The Week: Biotechs And A Grocery Outlet Benzinga
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. Atreca, Inc. was founded in 2010 and is headquartered in Redwood City, California.